$176.21
2.65% today
Nasdaq, Apr 03, 03:47 pm CET
ISIN
US5011471027
Symbol
KRYS

Krystal Biotech, Inc. Stock price

$181.00
+9.17 5.34% 1M
+3.62 2.04% 6M
+24.34 15.54% YTD
+4.09 2.31% 1Y
+107.93 147.71% 3Y
+141.42 357.30% 5Y
+170.36 1,601.13% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+6.42 3.68%
ISIN
US5011471027
Symbol
KRYS
Sector
Industry

Key metrics

Market capitalization $5.21b
Enterprise Value $4.62b
P/E (TTM) P/E ratio 60.58
EV/FCF (TTM) EV/FCF 38.80
EV/Sales (TTM) EV/Sales 15.92
P/S ratio (TTM) P/S ratio 17.95
P/B ratio (TTM) P/B ratio 5.51
Revenue growth (TTM) Revenue growth 473.02%
Revenue (TTM) Revenue $290.51m
EBIT (operating result TTM) EBIT $103.19m
Free Cash Flow (TTM) Free Cash Flow $119.18m
Cash position $597.52m
EPS (TTM) EPS $2.99
P/E forward 24.71
P/S forward 11.37
EV/Sales forward 10.09
Short interest 12.36%
Show more

Is Krystal Biotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Krystal Biotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Krystal Biotech, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Krystal Biotech, Inc. forecast:

Buy
91%
Hold
9%

Financial data from Krystal Biotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
291 291
473% 473%
100%
- Direct Costs 27 27
230% 230%
9%
264 264
519% 519%
91%
- Selling and Administrative Expenses 100 100
14% 14%
35%
- Research and Development Expense 54 54
15% 15%
18%
110 110
219% 219%
38%
- Depreciation and Amortization 6.67 6.67
33% 33%
2%
EBIT (Operating Income) EBIT 103 103
206% 206%
36%
Net Profit 89 89
716% 716%
31%

In millions USD.

Don't miss a Thing! We will send you all news about Krystal Biotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Krystal Biotech, Inc. Stock News

Positive
Seeking Alpha
10 days ago
Krystal Biotech's VYJUVEK, a first-mover gene therapy for DEB, has received a positive CHMP recommendation, potentially boosting its global market presence and valuation. Despite KRYS's premium valuation, its growth potential, strong financials, and first-mover advantage justify the market's appraisal, with a fair value estimate of $175-$185 per share. Key risks include regulatory setbacks, rei...
Neutral
GlobeNewsWire
about one month ago
PITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's)  announcement that its Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for the European Commission (EC) to approve VYJUVEK® (beremagene geperpavec-svdt, or B...
Positive
Seeking Alpha
about one month ago
Krystal Biotech's VYJUVEK shows strong growth, with 2025 sales expected to exceed $1B, bolstered by launches in the EU and Japan. Q4 earnings beat EPS expectations but slightly missed revenue forecasts; however, management's 2025 outlook coming catalysts drove a strong rally in shares. Key 2025 catalysts include VYJUVEK's EU and Japan launches, Phase 3 ocular DEB results, and progress in CF and...
More Krystal Biotech, Inc. News

Company Profile

Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.

Head office United States
CEO Krish Krishnan
Employees 275
Founded 2016
Website www.krystalbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today